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The ongoing MESAMI translational research program.
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Purpose: Despite the improvement of pharmacological and surgical thera-
pies, the mortality related to ischemic heart failure remains high. During the last
years, bone marrow-mesenchymal stem cell (BM-MSC) therapy has been pro-
posed as a novel approach for the prevention and therapy of heart failure.
Intramyocardial injection allows concentration of grafted cells within the injured
zone. However, a major problem of with intraparenchymal route of administra-
tion is the early death of most of grafted cells. The goal of the MESAMI program
is to evaluate the effect of intramyocardial administration of BM-MSC precondi-
tioned or not with the pineal hormone melatonin in ischemic cardiomyopathy.
Methods and Results: Our preclinical investigations have designed a pre-
conditioning strategy of BM-MSCs with the melatonin that significantly increases
survival and efficacy of grafted cells in animal models of myocardial ischemia.
Melatonin treatment significantly ameliorates the beneficial effects of BM-MSC
on the recovery of cardiac function. In the mean time, we started a phase I clinical
trial in patients with severe ischemic cardiomyopathy and no option of revascular-
ization, using the NOGA XP system to guide injections into the myocardium.
Based on our basic research results, we are developing a multicenter phase II trial
on the effects of intramyocardial administration of melatonin-preconditioned BM-
MSC in patients with chronic ischemic cardiomyopathy. 
Conclusion: The ongoing MESAMI program is representative of a trans-
lational research program in France. 
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Impact of immediate coronary angiography and new reanimation
techniques in cardiac arrest patients.
Johanne Silvain (1), Antoine Landivier (1), Olivier Barthelemy (1), Jean-
Louis Trouillet (2), Anne Bellemain-Appaix (1), Farzin Beygui (1), Jean-
Philippe Collet (1), Thomas Chastre (1), Gilles Montalescot (1), Charles-
Edouard Luyt (2)
(1) CHU Pitié-Salpetrière, Cardiologie, Paris, France – (2) Institut de
Cardiologie, Réanimation Médicale, Paris, France
Background: Prognosis of patients surviving having an out-of-hospital or
an in-hospital cardiac arrest is still very poor. Immediate coronary angiog-
raphy with successful angioplasty has shown to improve prognosis of these
patients. Nevertheless this strategy in the setting of new reanimation tech-
niques using hypothermia or cardiac assistance has not yet been evaluated.
Aim: To evaluate the impact of coronarography and ad hoc angioplasty on
survival rate. 
Methods: The Pitié-Salpêtrière registry included 328 consecutive patients
who survived a cardiac arrest and were transferred to the cath-lab for emer-
gency coronary angiography followed by ad-hoc PCI and state-of-the art crit-
ical care techniques. We present here intermediate results with the follow up
of 223 consecutive patients. 
Results: Most (65.7%) cardiac arrest survivors had angiographic coronary
artery disease (at least one lesion >70%), with an attempted angioplasty in
49.1% of the total patients and in 75% of patients with coronary artery dis-
ease. Angioplasty was successful in 82.4% of attempted PCI. Total hospital
survival rate was 43.8% when it was 45.7% in patients with CAD and 40.8%
in patients without CAD, p=0.1with non adjusted HR 1.09 (95% CI 0.7-1.6).
Survival rate was 48.3% in patients with successful PCI and 40.6% in patients
without PCI or PCI failure, p=0.3 with non adjusted HR 1.2(95% CI 0.8-1.8).
Complete follow up pf the cohort is pending. 
Conclusions: Two third of cardiac arrest survivors present with angio-
graphic coronary artery disease and undergo 75% of attempted PCI. In this
intermediate analysis presence of CAD and successful PCI provided trend in a
better survival but were not significantly associated with a better outcomes. 
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Resistance to antiplatelet therapy in the elderly, a real concern.
Results of the senior platelet study
Johanne Silvain, Guillaume Cayla, Ana Pena, Anne Bellemain-Appaix,
Farzin Beygui, Olivier Barthelemy, Sophie Galier, Benjamin Bertin, Jean-
Philippe Collet, Gilles Montalescot
CHU Pitié-Salpetrière, Cardiologie,Paris, France
Background: Dual antiplatelet therapy effect on platelet inhibition in eld-
erly patients (>75 y/o) is unknown as this growing proportion of ACS are
often excluded from clinical trials
Aim: To compare on-treatment platelet reactivity under dual antiplatelet
therapy of elderly (>75 yrs) vs. younger patients (< 75yrs). 
Methods: We included 652 coronary patients treated by aspirin and clopi-
dogrel in whom platelet response was assessed by light transmission aggre-
grometry with measure of Maximum (MPA) and Residual Platelet
Aggregation (RPA) and VerifyNow with PRU. The population was divided
in 5 age categories and compared with elderly patients >75 yrs. Rates of non-
response were established using admitted definitions.
Results: The mean MD of clopidogrel and aspirin were 86.6mg and 80.6
mg in patients <75 y/o respectively, and 81.8 mg and 78.6 mg in the elderly.
On-clopidogrel platelet reactivity was higher in elderly patients when com-
pared to younger patients whatever the test used (figure). The rate of non-
responders was 37.1% in the 105 elderly patients when assessed by PRU>235
and 19,01% in the 547 younger patients (<75 y/o; p<0,001). Results were even
more striking when RPA was considered with 67.3% non-responders in the
elderly patients vs. 22.8% in the 547 younger patients; p<0,001). Mean ARU
was similar in both groups with 440U in patients under 75 y/o vs. 452U in eld-
erly (p=0.8), but the mean AA induced MPA was 5.5% in patients under 75
y/o vs. 10.4% in elderly (p=0.01). The rate of non-response was 6.25% and
15% with LTA ( p=0.001).
Conclusions: Elderly patients have higher levels of on-treatment platelet
reactivity for both clopidogrel and aspirin and a 2-fold increase in the rate of
non-responders to clopidogrel and a 3-fold increase of non-responders to
aspirin, suggesting that they should not be undertreated. 
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